{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:25:28Z","timestamp":1793701528498,"version":"4.5.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aim of this study was to evaluate the prognostic value of tumor regression grade (TRG) in patients with esophageal cancer after neoadjuvant therapy and to validate the prognostic value of a novel TRG system (nTRG) system including the number of metastatic lymph node stations (S system) in patients with esophageal cancer after neoadjuvant therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A total of 514 patients were enrolled in the study cohort, and survival differences between categories of the TRG or S system were tested using the Kaplan\u2013Meier (KM) method and log-rank, with the former graded according to College of American Pathologists criteria. The nTRG system was developed by combining the two systems. We compared the discrimination, accuracy, and clinical value of the current American Joint Committee on Cancer (AJCC) post-neoadjuvant staging system (ypTNM) with the\u00a0nTRG, which integrates TRG and novel metastatic lymph node station number.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the training cohort, the discrimination, accuracy, and clinical value of nTRG staging groups were better than those of the ypTNM staging groups, which is reflected in the higher C-index and decision curve analysis values. Results were similar in the validation cohort. Multivariate analysis showed that nTRG stage (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001), smoking (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.02), and recurrence (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001) were independent prognostic factors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The nTRG staging system demonstrates superior predictive efficacy to the AJCC ypTNM staging system.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-18612-y","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T22:38:14Z","timestamp":1762727894000},"page":"996-1006","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic Value of a Novel Staging System Integrating Lymph Node Station Number and Tumor Regression Grade for Esophageal Cancer Following Neoadjuvant Chemoradiotherapy"],"prefix":"10.1245","volume":"33","author":[{"given":"Bo-Wei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Dan-Qi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Min","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Xin","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,9]]},"reference":[{"issue":"8","key":"18612_CR1","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1245\/s10434-010-0995-2","volume":"17","author":"DK Tong","year":"2010","unstructured":"Tong DK, Law S, Kwong DL, Chan KW, Lam AK, Wong KH. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor. Ann Surg Oncol. 2010;17(8):2184\u201392.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"18612_CR2","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1245\/s10434-019-07967-8","volume":"27","author":"FR Takeda","year":"2020","unstructured":"Takeda FR, Tustumi F, de Almeida Obregon C, et al. Prognostic value of tumor regression grade based on ryan score in squamous cell carcinoma and adenocarcinoma of esophagus. Ann Surg Oncol. 2020;27(4):1241\u20137.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"18612_CR3","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/jso.24151","volume":"113","author":"K Hatogai","year":"2016","unstructured":"Hatogai K, Fujii S, Kojima T, et al. Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery. J Surg Oncol. 2016;113(4):390\u20136.","journal-title":"J Surg Oncol."},{"issue":"9","key":"18612_CR4","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.ejso.2017.03.001","volume":"43","author":"G Tomasello","year":"2017","unstructured":"Tomasello G, Petrelli F, Ghidini M, et al. Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies. Eur J Surg Oncol. 2017;43(9):1607\u201316.","journal-title":"Eur J Surg Oncol."},{"issue":"7","key":"18612_CR5","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1097\/JTO.0000000000000580","volume":"10","author":"ZH Ning","year":"2015","unstructured":"Ning ZH, Wang ZG, Chen J, et al. Proposed modification of nodal staging as an alternative to the seventh edition of the american joint committee on cancer tumor-node-metastasis staging system improves the prognostic prediction in the resected esophageal squamous-cell carcinoma. J Thorac Oncol. 2015;10(7):1091\u20138.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"18612_CR6","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00268-011-1015-9","volume":"35","author":"QR Xu","year":"2011","unstructured":"Xu QR, Zhuge XP, Zhang HL, Ping YM, Chen LQ. The N-classification for esophageal cancer staging: should it be based on number, distance, or extent of the lymph node metastasis? World J Surg. 2011;35(6):1303\u201310.","journal-title":"World J Surg."},{"issue":"1","key":"18612_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1442-2050.2009.00971.x","volume":"23","author":"HL Zhang","year":"2010","unstructured":"Zhang HL, Chen LQ, Liu RL, et al. The number of lymph node metastases influences survival and International Union Against Cancer tumor-node-metastasis classification for esophageal squamous cell carcinoma. Dis Esophagus. 2010;23(1):53\u20138.","journal-title":"Dis Esophagus."},{"issue":"8","key":"18612_CR8","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1245\/s10434-018-6507-5","volume":"25","author":"H Miyata","year":"2018","unstructured":"Miyata H, Tanaka K, Makino T, et al. The Impact of pathological tumor regression and nodal status on survival and systemic disease in patients undergoing neoadjuvant chemotherapy for esophageal squamous cell carcinoma. Ann Surg Oncol. 2018;25(8):2409\u201317.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"18612_CR9","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1038\/bjc.2014.94","volume":"110","author":"T Schmidt","year":"2014","unstructured":"Schmidt T, Sicic L, Blank S, et al. Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas. Br J Cancer. 2014;110(7):1712\u201320.","journal-title":"Br J Cancer."},{"issue":"5","key":"18612_CR10","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1097\/01.sla.0000186170.38348.7b","volume":"242","author":"PM Schneider","year":"2005","unstructured":"Schneider PM, Baldus SE, Metzger R, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242(5):684\u201392.","journal-title":"Ann Surg."},{"issue":"19","key":"18612_CR11","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1002\/cam4.4748","volume":"11","author":"JK Yun","year":"2022","unstructured":"Yun JK, Kim Y, Lee GD, et al. Tumor regression grade combined with lymph node status in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy. Cancer Med. 2022;11(19):3623\u201332.","journal-title":"Cancer Med."},{"issue":"11","key":"18612_CR12","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C","volume":"73","author":"AM Mandard","year":"1994","unstructured":"Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11):2680\u20136.","journal-title":"Cancer."},{"issue":"5","key":"18612_CR13","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1097\/SLA.0000000000005636","volume":"276","author":"IYH Wong","year":"2022","unstructured":"Wong IYH, Chung JCY, Zhang RQ, et al. A novel tumor staging system incorporating tumor regression grade (TRG) with lymph node status (ypN-Category) results in better prognostication than ypTNM stage groups after neoadjuvant therapy for esophageal squamous cell carcinoma. Ann Surg. 2022;276(5):784\u201391.","journal-title":"Ann Surg."},{"issue":"6","key":"18612_CR14","doi-asserted-by":"publisher","first-page":"e1022","DOI":"10.1097\/SLA.0000000000003727","volume":"274","author":"X Leng","year":"2021","unstructured":"Leng X, He W, Yang H, et al. Prognostic impact of postoperative lymph node metastases after neoadjuvant chemoradiotherapy for locally advanced squamous cell carcinoma of esophagus: from the results of NEOCRTEC5010, a randomized multicenter study. Ann Surg. 2021;274(6):e1022\u20139.","journal-title":"Ann Surg."},{"issue":"23","key":"18612_CR15","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1200\/JCO.2015.65.7692","volume":"34","author":"EC Smyth","year":"2016","unstructured":"Smyth EC, Fassan M, Cunningham D, et al. Effect of pathologic tumor response and nodal status on survival in the medical research council adjuvant gastric infusional chemotherapy trial. J Clin Oncol. 2016;34(23):2721\u20137.","journal-title":"J Clin Oncol."},{"issue":"1","key":"18612_CR16","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.athoracsur.2015.06.081","volume":"101","author":"J Peng","year":"2016","unstructured":"Peng J, Wang WP, Dong T, Cai J, Ni PZ, Chen LQ. Refining the nodal staging for esophageal squamous cell carcinoma based on lymph node stations. Ann Thorac Surg. 2016;101(1):280\u20136.","journal-title":"Ann Thorac Surg."},{"issue":"11\u201312","key":"18612_CR17","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1080\/08941939.2022.2127036","volume":"35","author":"YM Gu","year":"2022","unstructured":"Gu YM, Lyu SM, Shang QX, et al. Is Tumor regression grade sufficient to predict survival in esophageal cancer with trimodal therapy? J Invest Surg. 2022;35(11\u201312):1818\u201323.","journal-title":"J Invest Surg."},{"issue":"4","key":"18612_CR18","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.athoracsur.2017.03.081","volume":"104","author":"F Wang","year":"2017","unstructured":"Wang F, Zheng Y, Wang Z, Zheng Q, Huang Q, Liu S. Nodal skip metastasis in esophageal squamous cell carcinoma patients undergoing three-field lymphadenectomy. Ann Thorac Surg. 2017;104(4):1187\u201393.","journal-title":"Ann Thorac Surg."},{"issue":"12","key":"18612_CR19","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1245\/s10434-019-07601-7","volume":"26","author":"Y Yuan","year":"2019","unstructured":"Yuan Y, Hong HG, Zeng X, et al. Lymph node station-based nodal staging system for esophageal squamous cell carcinoma: a large-scale multicenter study. Ann Surg Oncol. 2019;26(12):4045\u201352.","journal-title":"Ann Surg Oncol."},{"issue":"18","key":"18612_CR20","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/JCO.20.03614","volume":"39","author":"BM Eyck","year":"2021","unstructured":"Eyck BM, van Lanschot JJB, Hulshof MCCM, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol. 2021;39(18):1995\u20132004.","journal-title":"J Clin Oncol."},{"issue":"3","key":"18612_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008631","volume":"12","author":"X Xu","year":"2024","unstructured":"Xu X, Sun Z, Liu Q, et al. Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer. J Immunother Cancer. 2024;12(3):e008631.","journal-title":"J Immunother Cancer."},{"issue":"5","key":"18612_CR22","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1097\/SLA.0000000000004329","volume":"272","author":"IYH Wong","year":"2020","unstructured":"Wong IYH, Lam KO, Zhang RQ, et al. Neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil (PF) versus carboplatin and paclitaxel (CROSS Regimen) for esophageal squamous cell carcinoma (ESCC): a propensity score-matched study. Ann Surg. 2020;272(5):779\u201385.","journal-title":"Ann Surg."},{"issue":"6","key":"18612_CR23","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1245\/s10434-024-14941-6","volume":"31","author":"J Li","year":"2024","unstructured":"Li J, Zhou X, Liu Y, et al. Optimal Time-to-Surgery Recommendations Based on Primary Tumor Volume Regression for Patients with Resectable Esophageal Cancer after Neoadjuvant Chemoradiotherapy: A Retrospective Study. Ann Surg Oncol. 2024;31(6):3803\u201312.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"18612_CR24","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1186\/s12885-021-08838-w","volume":"21","author":"Y Chen","year":"2021","unstructured":"Chen Y, Huang Q, Chen J, et al. Primary gross tumor volume is prognostic and suggests treatment in upper esophageal cancer. BMC Cancer. 2021;21(1):1130.","journal-title":"BMC Cancer."},{"key":"18612_CR25","doi-asserted-by":"publisher","first-page":"1611844","DOI":"10.3389\/pore.2024.1611844","volume":"30","author":"P Chen","year":"2024","unstructured":"Chen P, Chen M, Bu Y, Che G, Cheng C, Wang Y. Prognostic role of lymph node regression in patients with esophageal cancer undergoing neoadjuvant therapy. Pathol Oncol Res. 2024;30:1611844.","journal-title":"Pathol Oncol Res."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18612-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18612-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18612-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:33:50Z","timestamp":1767573230000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18612-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,9]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["18612"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18612-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,9]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}